Synthesis and In vitro Anti-bladder Cancer Activity Evaluation of Quinazolinyl-arylurea Derivatives
Overview
Authors
Affiliations
Based on the structural modification of molecular-targeted agent sorafenib, a series of quinazolinyl-arylurea derivatives were synthesized and evaluated for their anti-proliferative activities against six human cancer cell lines. Compared with other cell lines tested, T24 was more sensitive to most compounds. Compound 7j exhibited the best profile with lower IC value and favorable selectivity. In this study, we focused on 7j-induced death forms of T24 cells and tried to elucidate the reason for its potent proliferative inhibitory activity. Compound 7j treatment could trigger three different cell death forms including apoptosis, ferroptosis, and autophagy; which form would occur depended on the concentrations and incubation time of 7j: (1) Lower concentrations within the initial 8 h of 7j treatment led to apoptosis-dependent death. (2) Ferroptosis and autophagy occurred in the case of higher concentrations combining with extended incubation time through effectively regulating the Sxc/GPx4/ROS and PI3K/Akt/mTOR/ULK1 pathways, respectively. (3) The above death forms were closely associated with intracellular ROS generation and decreased mitochondrial membrane potential induced by 7j. In molecular docking and structure-activity relationship analyses, 7j could bind well to the active site of the corresponding receptor glutathione peroxidase 4 (GPx4). Compound 7j could be a promising lead for molecular-targeted anti-bladder cancer agents' discovery.
Jin X, Jin W, Tong L, Zhao J, Zhang L, Lin N Acta Pharm Sin B. 2024; 14(7):2815-2853.
PMID: 39027232 PMC: 11252466. DOI: 10.1016/j.apsb.2024.04.020.
Relationship of mTORC1 and ferroptosis in tumors.
Liao H, Wang Y, Zou L, Fan Y, Wang X, Tu X Discov Oncol. 2024; 15(1):107.
PMID: 38583115 PMC: 10999401. DOI: 10.1007/s12672-024-00954-w.
Inaugurating a novel adjuvant therapy in urological cancers: Ferroptosis.
Xie Z, Zhou Q, Qiu C, Zhu D, Li K, Huang H Cancer Pathog Ther. 2024; 1(2):127-140.
PMID: 38328400 PMC: 10846326. DOI: 10.1016/j.cpt.2022.10.002.
Liu Z, Du D, Zhang S Toxicol Res (Camb). 2024; 13(1):tfae010.
PMID: 38292893 PMC: 10822837. DOI: 10.1093/toxres/tfae010.
Ma J, Hu J, Zhao L, Wu Z, Li R, Deng W BMC Urol. 2024; 24(1):6.
PMID: 38172792 PMC: 10765654. DOI: 10.1186/s12894-023-01354-y.